唐氏综合征患者脑β-淀粉样蛋白沉积的年龄依赖性：一项[18F]氟比他班PET研究。
Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.
作者信息
Jennings Danna, Seibyl John, Sabbagh Marwan, Lai Florence, Hopkins William, Bullich Santi, Gimenez Monica, Reininger Cornelia, Putz Barbara, Stephens Andrew, Catafau Ana M, Marek Ken
机构信息
From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
出版信息
Neurology. 2015 Feb 3;84(5):500-7. doi: 10.1212/WNL.0000000000001212. Epub 2015 Jan 7.
OBJECTIVE
To investigate brain β-amyloid binding in subjects with Down syndrome (DS) using [(18)F]florbetaben PET imaging.
METHODS
Thirty-nine subjects with DS (46.3 ± 4.7 years) were assessed with [(18)F]florbetaben PET imaging. Three blinded independent readers assessed the scans to provide a visual analysis. The primary quantitative imaging outcome was a standardized uptake value ratio (SUVR) obtained for 6 brain regions. Cognitive status was evaluated using the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID).
RESULTS
[(18)F]Florbetaben uptake was correlated with age (p < 0.0001, R(2) = 0.39); 90% of scans in subjects with DS aged 50 years or older (SUVR = 1.62 ± 0.26), 53% in those aged 45 to 49 years (SUVR = 1.43 ± 0.16), and 7% in those aged 40 to 45 years (SUVR = 1.27 ± 0.11) were visually assessed as positive. Visual and quantitative assessments were highly related (χ(2) = 11.3823, p = 0.0007; Cohen κ = 0.58). Only 2 of 34 participants were considered to have dementia by the DSQIID.
CONCLUSIONS
Brain β-amyloid binding, as measured by [(18)F]florbetaben, increases with age in DS. Subjects with DS who have no evidence of dementia demonstrate brain β-amyloid binding in vivo, suggesting that [(18)F]florbetaben PET imaging may detect β-amyloid in this at-risk population.
目的
使用[（18）F]氟比他班PET成像研究唐氏综合征（DS）患者的脑β淀粉样蛋白结合情况。
方法
对39名DS患者（46.3±4.7岁）进行[（18）F]氟比他班PET成像评估。三名盲法独立阅片者对扫描结果进行评估以提供视觉分析。主要的定量成像结果是6个脑区的标准化摄取值比率（SUVR）。使用《智障者痴呆筛查问卷》（DSQIID）评估认知状态。
结果
[（18）F]氟比他班摄取与年龄相关（p<0.0001，R² = 0.39）；50岁及以上DS患者中90%的扫描结果（SUVR = 1.62±0.26）、45至49岁患者中53%的扫描结果（SUVR = 1.43±0.16）以及40至45岁患者中7%的扫描结果（SUVR = 1.27±0.11）经视觉评估为阳性。视觉评估和定量评估高度相关（χ² = 11.3823，p = 0.0007；Cohen κ = 0.58）。在34名参与者中，只有2人被DSQIID判定为患有痴呆。
结论
通过[（18）F]氟比他班测量的脑β淀粉样蛋白结合在DS患者中随年龄增加。无痴呆证据的DS患者在体内表现出脑β淀粉样蛋白结合，这表明[（18）F]氟比他班PET成像可能在这个高危人群中检测到β淀粉样蛋白。
Zotero 插件